Re-appointment of Managing Director: Mr. Santosh Vora (DIN: 07633923) re-appointed as Managing Director for five years effective February 06, 2027, subject to shareholder approval via Special Resolution at ensuing AGM. He holds a bachelor's degree in commerce with specialization in Financial Markets from University of Mumbai and completed Post Graduate Programme in Management for Family Business from ISB Hyderabad. He has over 8 years of experience in chemical and pharmaceutical industry, specializing in new product development and process optimization.
Re-appointment of Independent Director: Mrs. Sonal Vira (DIN: 09505883) re-appointed as Independent Director for second term of five years effective February 16, 2027, subject to shareholder approval. She is a Commerce graduate from University of Mumbai and Chartered Accountant from ICAI with over 15 years of experience in corporate banking. She confirmed meeting independence criteria under Companies Act, 2013 and Listing Regulations.
Continuation of Non-Executive Non-Independent Director: Mr. Shantilal Vora (DIN: 07633852) to continue as Non-Executive Non-Independent Director upon attaining age of 75 years effective November 05, 2027, subject to shareholder approval under Regulation 17(1A) of Listing Regulations. He has over 45 years of experience in chemical and pharmaceutical industry, specializing in sales and marketing of bulk drugs.
Director Relationships: Mr. Santosh Vora is son of Mr. Shantilal Vora. Mr. Shantilal Vora is father of Mr. Santosh Vora. Mrs. Sonal Vira is not related to any director.
Eligibility Confirmation: All three directors are not debarred from holding office by SEBI or any other authority.
Key Financial or Operational Approvals
Investment in Wholly Owned Subsidiary: Approved additional investment of up to ₹60 crore in Valiant Advanced Sciences Private Limited (VASPL) by subscribing to 1% Optionally Convertible Redeemable Preference Shares in one or more tranches. Investment to be completed within 12 months from approval date.
Purpose of Investment: To meet working capital requirements and general corporate purposes of VASPL, and to strengthen its capital base. Company's 100% shareholding in VASPL will remain unchanged.
VASPL Financials (as of March 31, 2026):
Net worth: ₹15,618.41 Lakh
Turnover (FY 2025-26): ₹4,164.86 Lakh
Turnover (FY 2024-25): ₹2.02 Lakh
Turnover (FY 2023-24): ₹0.48 Lakh
Transaction Nature: Related party transaction at arm's length basis. No governmental approvals required beyond corporate approvals under Companies Act, 2013.
Strategic or Business Context
Registered Office Shift: Approved shifting of registered office from 104, Udyog Kshetra, Mulund-Goregaon Link Road, Mulund (West), Mumbai – 400080 to Plot No. L-13, L-28, L-28(Pt), L-29 & L-30, MIDC Tarapur, Boisar, Palghar, Maharashtra – 401506, changing jurisdiction from ROC Mumbai-I to ROC Mumbai-II (Navi Mumbai). Subject to shareholder approval and Regional Director, Western Region confirmation.
New Corporate Office: Approved opening of new corporate office at 701, Tower B, Embassy 247 Park, LBS Road, Vikhroli (West), Mumbai – 400083 for administrative, management, finance, secretarial and other corporate functions.
Business Alignment: VASPL's speciality chemicals business (manufacturing acetic anhydride, ketene and diketene derivatives) is not outside main line of business of Valiant Laboratories Limited.
Any Other Material Information
Board Meeting Timing: Held on August 10, 2026 from 04:30 p.m. to 06:00 p.m.
Approval Requirements: All reappointments and continuations subject to shareholder approval via Special Resolution at ensuing Annual General Meeting.
Compliance Reference: Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
